|Systematic (IUPAC) name|
|Trade names||Alphagan, Mirvaso|
|Pregnancy cat.||B (US)|
|Legal status||℞-only (US)|
|Routes||Ocular, 1 drop|
|ATC code||D11 S01|
|Mol. mass||292.135 g/mol|
|(what is this?)|
It acts via decreasing synthesis of aqueous humor, and increasing the amount that drains from the eye through uveoscleral outflow. As a treatment for glaucoma, it is usually given in eyedrop form.
Mechanism of action
Peripheral alpha 2 agonist activity results in vasoconstriction of blood vessels (as opposed to central alpha 2 agonist activity that decreases sympathetic tone, as can be seen by the medication clonidine). This vasoconstriction may explain the acute reduction in aqueous humor flow. The increased uveoscleral outflow from prolonged use may be explained by increased prostaglandin release due to alpha adrenergic stimulation. This may lead to relaxed ciliary muscle and increased uveoscleral outflow.
In 2013, the FDA approved topical application of brimonidine 0.33% (Mirvaso) for facial erythema or rosacea.
- Mosby's Drug Guide for Nurses (7th edition; Skidmore) 2007.